Serum Level of Tumor-Specific Growth Factor in Patients with Cervical Cancer and Its Potential Prognostic Role

Background: Tumor-specific growth factor (TSGF) is associated with invasion and metastasis of various malignancies adverse clinical outcomes. TSGF also highly expressed in cervical cancer (CC), but its value unclear. Materials Methods: Serum samples from malignancies, including CC, non-Hodgkin’s lymphoma (NHL), nasopharyngeal carcinoma (NPC), colorectal (CRC), lung (LCA), ovarian (OC), breast (BC), gastric (GC), pancreatic (PC) were collected, was detected using a chemiluminescence assay. The patients CC followed-up over five years, their clinicopathological parameters analyzed. Meanwhile, the pre- post-treatment levels compared. predictive prognostic roles evaluated Kaplan-Meier survival curves, multivariate COX analyses, ROC curves. Results: CRC, OC had higher serum than healthy population (P < 0.05), that other cancers 0.05). Clinicopathologic analysis showed linked to tumor size, depth, histologic grade, International Federation Gynecology Obstetrics (FIGO) stage, high sensitivity 56%. significantly decreased curves identified as significant poor predictor metastasis-free, recurrence-free, overall (OS). Multivariate analyses an independent for OS rate. curve revealed ability predict recurrence, while cut-off 66.94 U/mL. notably post-therapeutic gradually treatment progress. Conclusions: may be novel potential indicator predicting prognosis recurrence after surgery adjuvant therapy CC.